학술논문
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial
Document Type
Article
Author
Ogbuagu, O.; Segal-Maurer, S.; Ratanasuwan, W.; Avihingsanon, A.; Brinson, C.; Workowski, K.; Antinori, A.; Yazdanpanah, Y.; Trottier, B.; Wang, H.; Margot, N.; Dvory-Sobol, H.; Rhee, M.S.; Baeten, J.M.; Molina, J.-M.; Molina, J.-M.; Molina, J.-M.; DeJesus, E.; Richmond, G.J.; Berhe, M.; Ruane, P.J.; Sinclair, G.I.; Lichtenstein, K.; Ramgopal, M.N.; Wiznia, A.; Workowski, K.; Sanchez, W.; Brinson, C.; McGowan, J.P.; Creticos, C.M.; Berger, D.S.; Wheeler, D.A.; Hagins, D.; Crofoot, G.E.; Sims, J.; Osiyemi, O.; Hodge, T.; Zurawski, C.; Ogbuagu, O.; Segal-Maurer, S.; Ratanasuwan, W.; Siripassorn, K.; Chetchotisakd, P.; Castagna, A.; Castelli, F.; Ronot-Bregigeon, S.; Molina, J.-M.; Trottier, B.; Brunetta, J.; Shirasaka, T.; Yokomaku, Y.; Koenig, E.; Mallolas, J.; Stellbrink, H.-J.; Hung, C.-C.; Rassool, M.
Source
In: The Lancet HIV . (The Lancet HIV, August 2023, 10(8):e497-e505)
Subject
Language
English
ISSN
23523018